BNGO Logo.png
Bionano Announces Glass Lewis Recommendation and Encourages Stockholders to Cast their Vote Ahead of June 9th Annual Meeting
May 26, 2022 19:39 ET | Bionano Genomics
SAN DIEGO, May 26, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of NxClinical™ software, the...
myriad_S_stacked.png
Myriad Genetics Showcases Advancements in Precision Medicine with Recent Oncology Portfolio Expansion and New Data Presentations at ASCO 2022
May 26, 2022 18:30 ET | Myriad Genetics, Inc.
SALT LAKE CITY, May 26, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will present multiple studies at the 2022 American Society...
Biomea-Fusion_Logo_RGB_rev2_Email.png
Biomea Fusion to Present New Preclinical Data Showing BMF-219’s Strong Activity in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Tumor Models at ASCO 2022
May 26, 2022 18:30 ET | Biomea Fusion, Inc.
BMF-219 is the first investigational menin inhibitor in clinical development to show potential as a therapeutic agent for CLLBMF-219, a covalent menin inhibitor, demonstrated potency across ex...
VMDlogo.jpg
Viemed Healthcare to Host Investor Webcast
May 26, 2022 18:15 ET | Viemed Healthcare, Inc.
LAFAYETTE, La., May 26, 2022 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the “Company” or “Viemed”) (NASDAQ:VMD and TSX:VMD.TO), a home medical equipment supplier and the nation’s largest...
immunocore-logo-2018
Immunocore announces upcoming presentations at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
May 26, 2022 18:00 ET | Immunocore Holdings Limited
PRESS RELEASE Immunocore announces upcoming presentations at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting Updated overall survival (OS) data from Phase 1b metastatic...
MamaMancini's logo
MamaMancini’s Holdings, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 10-K
May 26, 2022 17:30 ET | MamaMancini's Holdings, Inc.
EAST RUTHERFORD, NJ, May 26, 2022 (GLOBE NEWSWIRE) -- MamaMancini's Holdings, Inc. (NASDAQ: MMMB)(the “Company”), a marketer and distributor of specialty pre-prepared all-natural foods today...
Candel_Logo_FullColor (4).png
Candel Therapeutics Announces Release of Initial Data on CAN-2409 in a Phase 2 Clinical Trial Showing Cytotoxic T Cell Response and Disease Control in Patients with Non-Small Cell Lung Cancer
May 26, 2022 17:30 ET | Candel Therapeutics
Disease control rate of 87.5 percent achieved in patients who were all progressing on anti-PD-1 therapy at trial entryDurable disease stabilization that was ongoing at data cutoff in 62.5 percent of...
Immuneering-logo (1).png
Immuneering Reports Data in Two Preclinical Abstracts at the ASCO 2022 Annual Meeting Highlighting Pan-KRAS/NRAS Activity of IMM-1-104
May 26, 2022 17:26 ET | Immuneering Corporation
IMM-1-104 strongly inhibits tumor growth in an animal model of KRAS-G12V mutant pancreatic cancer Preclinical data package now includes animal studies showing the potential for broad activity across...
R_Logo_Color_DarkFont.png
SpringWorks Therapeutics Highlights Nirogacestat Clinical Data at the 2022 ASCO Annual Meeting
May 26, 2022 17:15 ET | SpringWorks Therapeutics, Inc.
- Initial Data to be Presented from GSK-Sponsored Phase 1/2 Study Evaluating Nirogacestat in Combination with Low-Dose BLENREP in Patients with Relapsed or Refractory Multiple Myeloma - - Long-Term...
Oncternal.png
Oncternal Therapeutics Presents Updated Interim Data for Zilovertamab in Combination with Ibrutinib at ASCO 2022
May 26, 2022 17:15 ET | Oncternal Therapeutics
Updated MCL and CLL data from the CIRLL study are encouraging and continue to improveORR of 85% (23 of 27 evaluable patients) and CR rate of 41% (11 of 27 evaluable patients) for patients with MCL...